// App-Quantinova.ai

12 : Effect of Certolizumab Pegol Over 48 Weeks on Signs and Symptoms in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure

Researchers

Presenter

  • Michael Maldonado

Principal Investigators

  • Jurgen Wollenhaupt

  • Atul Deodhar

  • Dafna Gladman

  • Christian Stach

  • Bengt Hoepken

  • Luke Peterson

  • Desiree Van der Heijde

Medical Centers

  • Univ of Toronto, Toronto, Canada

Locations

  • Canada

Companies

  • Bristol-Myers Squibb

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Malondialdehyde

  • Tumor necrosis factor

  • Albumin/creatinine

Drug/Treatment

  • Certolizumab pegol

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved